Arash Kazemi1, Jay W McLaren1, Casey C Kopczynski2,3, Theresa G Heah2,3, Gary D Novack4,5, Arthur J Sit1. 1. 1 Department of Ophthalmology, Mayo Clinic , Rochester, Minnesota. 2. 2 Aerie Pharmaceuticals, Inc. , Bedminster, New Jersey. 3. 3 Aerie Pharmaceuticals, Inc. , Durham, North Carolina. 4. 4 Departments of Ophthalmology and Pharmacology, University of California , Davis, California. 5. 5 PharmaLogic Development, Inc. , San Rafael, California.
Abstract
PURPOSE: Netarsudil, an inhibitor of Rho kinase and a norepinephrine transporter, has been shown to lower elevated intraocular pressure (IOP) in controlled studies of patients with open-angle glaucoma and ocular hypertension, and in healthy volunteers. The mechanism of this ocular hypotensive effect in humans is unknown. METHODS: The objective of this study was to evaluate the effect of netarsudil 0.02% on aqueous humor dynamics (AHD) parameters. In this double-masked, vehicle-controlled, paired-eye comparison study, 11 healthy volunteers received topical netarsudil ophthalmic solution 0.02% or its vehicle once daily for 7 days (morning dosing). The primary endpoints were the change in AHD parameters, compared between active and vehicle-treated eyes. RESULTS: In netarsudil-treated eyes, diurnal outflow facility increased from 0.27 ± 0.10 μL/min/mmHg to 0.33 ± 0.11 μL/min/mmHg (+22%; P = 0.02) after 7 days of treatment. In placebo-treated eyes, diurnal outflow facility did not significantly change (P = 0.94). The difference between netarsudil and placebo eyes in diurnal change of outflow facility was 0.08 μL/min/mmHg (P < 0.001). Diurnal episcleral venous pressure (EVP) in netarsudil-treated eyes decreased from 7.9 ± 1.2 mmHg to 7.2 ± 1.8 (-10%; P = 0.01). Diurnal EVP was not significantly different between netarsudil- and placebo-treated eyes. There was a trend toward decreasing aqueous humor flow rate (-15%; P = 0.08). No treatment changes were seen in uveoscleral outflow rate. CONCLUSIONS: Once-daily dosing of netarsudil ophthalmic solution 0.02% lowered IOP through increasing trabecular outflow facility and reducing EVP. This suggests a combination of mechanisms that affect both the proximal and distal outflow pathways.
RCT Entities:
PURPOSE:Netarsudil, an inhibitor of Rho kinase and a norepinephrine transporter, has been shown to lower elevated intraocular pressure (IOP) in controlled studies of patients with open-angle glaucoma and ocular hypertension, and in healthy volunteers. The mechanism of this ocular hypotensive effect in humans is unknown. METHODS: The objective of this study was to evaluate the effect of netarsudil 0.02% on aqueous humor dynamics (AHD) parameters. In this double-masked, vehicle-controlled, paired-eye comparison study, 11 healthy volunteers received topical netarsudil ophthalmic solution 0.02% or its vehicle once daily for 7 days (morning dosing). The primary endpoints were the change in AHD parameters, compared between active and vehicle-treated eyes. RESULTS: In netarsudil-treated eyes, diurnal outflow facility increased from 0.27 ± 0.10 μL/min/mmHg to 0.33 ± 0.11 μL/min/mmHg (+22%; P = 0.02) after 7 days of treatment. In placebo-treated eyes, diurnal outflow facility did not significantly change (P = 0.94). The difference between netarsudil and placebo eyes in diurnal change of outflow facility was 0.08 μL/min/mmHg (P < 0.001). Diurnal episcleral venous pressure (EVP) in netarsudil-treated eyes decreased from 7.9 ± 1.2 mmHg to 7.2 ± 1.8 (-10%; P = 0.01). Diurnal EVP was not significantly different between netarsudil- and placebo-treated eyes. There was a trend toward decreasing aqueous humor flow rate (-15%; P = 0.08). No treatment changes were seen in uveoscleral outflow rate. CONCLUSIONS: Once-daily dosing of netarsudil ophthalmic solution 0.02% lowered IOP through increasing trabecular outflow facility and reducing EVP. This suggests a combination of mechanisms that affect both the proximal and distal outflow pathways.
Authors: Richard A Lewis; Brian Levy; Nancy Ramirez; Casey C Kopczynski; Dale W Usner; Gary D Novack Journal: Br J Ophthalmol Date: 2015-07-24 Impact factor: 4.638
Authors: Arash Kazemi; Jay W McLaren; Shuai-Chun Lin; Carol B Toris; Vikas Gulati; Sayoko E Moroi; Arthur J Sit Journal: Invest Ophthalmol Vis Sci Date: 2017-01-01 Impact factor: 4.799
Authors: Kelly A Leary; Kuan-Ting Lin; Juan P Steibel; Christine D Harman; András M Komáromy Journal: Vet Ophthalmol Date: 2019-12-24 Impact factor: 1.644
Authors: Kelly A Leary; Juan P Steibel; Christine D Harman; Amanda L Anderson; András M Komáromy Journal: Vet Ophthalmol Date: 2021-06-04 Impact factor: 1.644
Authors: Haochen Xu; Marwa T Thomas; Dayeong Lee; Matthew T Hirabayashi; Jella A An Journal: Graefes Arch Clin Exp Ophthalmol Date: 2022-03-11 Impact factor: 3.535